KINGSWAY REPORTS FULL YEAR 2022 FINANCIAL RESULTS
Kingsway Financial Services (KFS) reported notable achievements for the 12 months ending December 31, 2022. The company completed a railyard sale for $215.2 million, netting $21.4 million post-expenses. It acquired Secure Nursing Service for $10.9 million and CSuite Financial Partners for $8.5 million, both expected to be accretive. Kingsway closed a debt facility amendment allowing an additional $10 million draw, while planning to repurchase most of its trust preferred debt. Total revenue rose to $93.3 million, driven by solid performance in Extended Warranty and Kingsway Search Xcelerator segments. Adjusted EBITDA improved to $10.2 million from $7.1 million in 2021.
- Total revenue increased to $93.3 million in 2022, up from $78.4 million in 2021.
- Adjusted EBITDA rose to $10.2 million for 2022, compared to $7.1 million in 2021.
- Acquisition of Secure Nursing Service and CSuite expected to be immediately accretive.
- Unrestricted cash increased to $64.2 million from $10.1 million year-over-year.
- Extended Warranty revenue decreased to $74.0 million in 2022 from $74.9 million in 2021.
- Pro forma revenue dropped slightly to $69.2 million in 2022 from $66.9 million in 2021.
Management to Host Conference Call Today at
Recent Business Highlights
- Completed the sale of its railyard in
Texas for , consisting of$215.2 million cash and$44.5 million of mortgage assumption, resulting in net proceeds to Kingsway of$170.7 million after taxes, fees and distribution to the minority shareholder$21.4 million Acquired Secure Nursing Service, Inc. ("SNS") onNovember 18, 2022 , a privately held, healthcare supplemental staffing agency, for ; the acquisition is expected to be immediately accretive, having pre-acquisition GAAP income before income taxes of$10.9 million and$2.6 million of unaudited adjusted EBITDA$2.7 million Acquired CSuite Financial Partners ("CSuite") onNovember 1, 2022 , a national, financial executive services firm, for ; the acquisition is expected to be immediately accretive, having pre-acquisition GAAP income before income taxes of$8.5 million and$0.9 million of unaudited adjusted EBITDA$1.8 million - On
February 28, 2023 , closed on an amendment to an existing debt facility (secured by its extended warranty companies) that allows the Company to draw up to in additional principal, in increments of at least$10 million , until$2 million February 27, 2024 - On
March 2, 2023 , the Company announced its intention to exercise its right to repurchase100% of the principal and deferred interest from five of the six trust preferred debt instruments no later thanMarch 15, 2023 ; as a result, the Company will also pay the deferred interest owed on the sixth trust preferred debt instrument and redeem any outstanding Class A Preferred Shares, both no later thanMarch 15, 2023
"2022 was a year of significant accomplishments and progress towards our strategic priorities," said
"We continue to simplify our balance sheet and capital structure, through actions such as selling our railyard asset and other non-core real estate assets," said
Full Year 2022 Consolidated Financial Highlights
As a result of the sale of its railyard assets, as well as the fact that the Company determined that its VA
Financial highlights include:
- Total revenue was
for 2022, compared to$93.3 million for 2021, and now consists of just Extended Warranty and Kingsway Search Xcelerator ("KSX") segment revenues$78.4 million - Extended Warranty revenue was
for 2022, compared to$74.0 million in 2021; however, pro forma revenue was$74.9 million for 2022, compared to$69.2 million for 2021 (pro forma excludes the results of PWSC, which was sold in$66.9 million July 2022 ) - KSX revenue was
for 2022, compared to$19.2 million for 2021 (the KSX segment was created when Ravix was acquired in$3.5 million October 2021 ) - Income from continuing operations was
for 2022, compared to a loss from continuing operations of$30.1 million in 2021$2.7 million - Adjusted EBITDA (a non-GAAP metric) was
for 2022, compared to adjusted EBITDA of$10.2 million in 2021$7.1 million - Extended Warranty segment and KSX segment operating income was a total of
in 2022, compared to a total of$13.4 million in 2021$13.1 million - Pro forma adjusted EBITDA for the Extended Warranty segment and KSX segment was a total of
in 2022, compared to a total of$13.5 million in 2021$9.4 million - Unrestricted cash and cash equivalents were
as of$64.2 million December 31, 2022 compared to as of$10.1 million December 31, 2021
The pro forma results above exclude the results of PWSC in 2021 and through the date of sale in
Reconciliations of GAAP to non-GAAP metrics are presented in the attached schedules. The Company today also filed its 2022 Annual Report on Form 10-K.
Conference Call and Webcast
Management will host a conference call at
Conference Call Information
Date:
Time:
Toll Free: 888-506-0062; Code: 295056
International: 973-528-0011; Code: 295056
Live Webcast Link: https://www.webcaster4.com/Webcast/Page/2928/47683
Conference Call Replay Information
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 47683
Replay Webcast Link: https://www.webcaster4.com/Webcast/Page/2928/47683
About the Company
Kingsway is a holding company that owns or controls subsidiaries primarily in the extended warranty and business services industries. The common shares of Kingsway are listed on the
The Company serves the extended warranty industry through its operating subsidiaries IWS (iwsgroup.com), Penn Warranty (pennwarranty.com), Preferred Warranties (preferredwarranties.com) and Trinity Warranty Solutions (trinitywarranty.com).
The Company serves the business services industry through its operating subsidiaries CSuite (csuitefinancialpartners.com), Ravix (ravixgroup.com) and Secure Nursing Service (securenursing.com).
Non
The Company believes that non-GAAP adjusted EBITDA, when presented in conjunction with comparable GAAP measures, provides useful information about the Company's operating results and enhances the overall ability to assess the Company's financial performance. The Company uses non-GAAP adjusted EBITDA, together with other measures of performance under GAAP, to compare the relative performance of operations in planning, budgeting and reviewing the performance of its business. Non-GAAP adjusted EBITDA allow investors to make a more meaningful comparison between the Company's core business operating results over different periods of time. The Company believes that non-GAAP adjusted EBITDA, when viewed with the Company's results under GAAP and the accompanying reconciliations, provides useful information about the Company's business without regard to potential distortions. By eliminating potential differences in results of operations between periods caused by the factors listed in the attached schedules, the Company believes that non-GAAP adjusted EBITDA can provide useful additional basis for comparing the current performance of the underlying operations being evaluated. Investors should consider this non-GAAP measure in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. Investors are encouraged to review the Company's financial results prepared in accordance with GAAP to understand the Company's performance taking into account all relevant factors.
Forward-Looking Statements
This press release and/or Shareholder Letter may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. Words such as "expects," "believes," "anticipates," "intends," "estimates," "seeks" and variations and similar words and expressions are intended to identify such forward-looking statements; however, the absence of any such words does not mean that a statement is a not a forward-looking statement. Such forward-looking statements relate to future events or future performance, but reflect Kingsway management's current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the section entitled "Risk Factors" in the Company's 2022 Annual Report on Form 10-K and subsequent Form 10-Qs and Form 8-Ks filed with the
Additional Information
Additional information about Kingsway, including a copy of its Annual Reports can be accessed on the EDGAR section of the
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA
(in thousands)
(UNAUDITED)
Twelve | For the Three Months Ended | ||||||||||||||||||
GAAP Net Income (Loss) | $ | 15,065 | $ | (17,339) | $ | 37,273 | $ | (2,365) | $ | (2,504) | |||||||||
Non-GAAP Adjustments: | |||||||||||||||||||
Discontinued operations | 15,067 | 15,678 | 1,670 | (786) | (1,495) | ||||||||||||||
Gain on sale of PWSC (1) | (26,447) | - | (26,447) | - | - | ||||||||||||||
Changes in fair value; realized gains/losses (2) | (10,649) | (1,249) | (13,914) | 2,479 | 2,035 | ||||||||||||||
Employee related expenses (3) | 2,653 | 670 | 321 | 507 | 1,155 | ||||||||||||||
Other items (4) | 1,172 | 1,532 | 184 | 86 | (630) | ||||||||||||||
Depreciation, amortization, tax and interest | 13,305 | 4,053 | 3,573 | 3,218 | 2,461 | ||||||||||||||
Total Non-GAAP Adjustments | (4,899) | 20,684 | (34,613) | 5,504 | 3,526 | ||||||||||||||
Non-GAAP Adjusted EBITDA (6) | $ | 10,166 | $ | 3,345 | $ | 2,660 | $ | 3,139 | $ | 1,022 | |||||||||
Includes reduction due to IWS change in | $ | 944 | $ | - | $ | - | $ | - | $ | 944 |
Twelve | For the Three Months Ended | ||||||||||||||||||
GAAP Net Income (Loss) | $ | 1,860 | $ | 1,443 | $ | (226) | $ | (256) | $ | 899 | |||||||||
Non-GAAP Adjustments: | |||||||||||||||||||
Discontinued operations | (4,573) | (1,755) | (1,066) | (524) | (1,228) | ||||||||||||||
Changes in fair value; realized gains/losses (2) | 907 | 412 | (857) | (20) | 1,372 | ||||||||||||||
Employee related expenses (3) | 3,859 | 692 | 574 | 735 | 1,858 | ||||||||||||||
Other items (4) | 208 | 300 | 209 | - | (301) | ||||||||||||||
PPP forgiveness (5) | (2,494) | - | - | - | (2,494) | ||||||||||||||
Depreciation, amortization, tax and interest | 7,376 | 2,538 | 1,518 | 1,731 | 1,589 | ||||||||||||||
Total Non-GAAP Adjustments | 5,283 | 2,187 | 378 | 1,922 | 796 | ||||||||||||||
Non-GAAP Adjusted EBITDA (6) | $ | 7,143 | $ | 3,630 | $ | 152 | $ | 1,666 | $ | 1,695 | |||||||||
Includes reduction due to PWI final | $ | 1,857 | $ | - | $ | 1,857 | $ | - | $ | - |
(1) | Gain on sale of PWSC, net of transaction expenses that are included in consolidated operating expenses, as well as income taxes associated with the sale. The Company estimates that had the gain not occurred, the Company would have recorded a tax benefit; therefore taxes of
|
(2) | Includes realized and unrealized gains and losses on non-core investments; change in the fair value of subordinated debt (net of the portion of the change attributable to instrument-specific credit risk); unrealized gain on the change in fair value of the trust preferred security options; and change in the fair value of the Ravix earn-out (changes in fair value recorded as other income or expense).
|
(3) | Employee related expenses includes charges relating to severance and consulting agreements pertaining to former key employees; and non-cash expense arising from the grant and modification of stock-based awards to employees. |
(4) | Other items includes: legal expenses associated with the Company's defense against significant litigation matters; acquisition-related expenses; expense relating to the settlement of all remaining Amigo claims; other non-recurring items; and net expense incurred as a result of legal settlement reached with DGI in Q1 2021.
|
(5) | Given the non-recurring nature of the PPP forgiveness benefit, the Company concluded this should be excluded from non-GAAP adjusted EBITDA.
|
(6) | Includes the results of PWSC through the date of sale (end of July 2022).
|
(7) | The three months ended |
Reconciliation of Extended Warranty Segment Operating Income to Non-GAAP Adjusted EBITDA
and Pro Forma Non-GAAP Adjusted EBITDA
(in thousands)
(UNAUDITED)
Twelve | For the Three Months Ended | |||||||||||||||||||||||||||||||||||||||
GAAP Operating Income for Extended | $ | 9,879 | $ | 2,759 | $ | 2,461 | $ | 2,936 | $ | 1,723 | ||||||||||||||||||||||||||||||
Non-GAAP Adjustments: | ||||||||||||||||||||||||||||||||||||||||
Investment income (1) | 510 | 193 | 145 | 96 | 76 | |||||||||||||||||||||||||||||||||||
Gain (loss) on sale of core investments (2) | (45) | (23) | (2) | (16) | (4) | |||||||||||||||||||||||||||||||||||
Depreciation | 292 | 61 | 70 | 87 | 74 | |||||||||||||||||||||||||||||||||||
Total Non-GAAP Adjustments | 757 | 231 | 213 | 167 | 146 | |||||||||||||||||||||||||||||||||||
Non-GAAP adjusted EBITDA for Extended | $ | 10,636 | $ | 2,990 | $ | 2,674 | $ | 3,103 | $ | 1,869 | ||||||||||||||||||||||||||||||
PWSC operating (income) loss (3) | (888) | - | 147 | (737) | (298) | |||||||||||||||||||||||||||||||||||
PWSC depreciation (3) | (44) | - | (8) | (25) | (11) | |||||||||||||||||||||||||||||||||||
Pro forma Non-GAAP adjusted EBITDA for | $ | 9,704 | $ | 2,990 | $ | 2,813 | $ | 2,341 | $ | 1,560 | ||||||||||||||||||||||||||||||
Includes reduction due to IWS change in estimate | $ | 944 | $ | - | $ | - | $ | - | $ | 944 |
Twelve | For the Three Months Ended | ||||||||||||||||||||||||||||||||||||||
GAAP Operating Income for Extended | $ | 12,636 | $ | 3,326 | $ | 1,400 | $ | 2,600 | $ | 5,310 | |||||||||||||||||||||||||||||
Non-GAAP Adjustments: | |||||||||||||||||||||||||||||||||||||||
Investment income (1) | 203 | 52 | 66 | 42 | 43 | ||||||||||||||||||||||||||||||||||
Gain (loss) on sale of core investments (2) | 14 | 19 | (18) | 1 | 12 | ||||||||||||||||||||||||||||||||||
PPP forgiveness (5) | (2,183) | - | - | - | (2,183) | ||||||||||||||||||||||||||||||||||
Depreciation | 215 | 95 | 55 | 53 | 12 | ||||||||||||||||||||||||||||||||||
Total Non-GAAP Adjustments | (1,751) | 166 | 103 | 96 | (2,116) | ||||||||||||||||||||||||||||||||||
Non-GAAP adjusted EBITDA for Extended | $ | 10,885 | $ | 3,492 | $ | 1,503 | $ | 2,696 | $ | 3,194 | |||||||||||||||||||||||||||||
PWSC operating income (3) | (1,958) | (552) | (503) | (500) | (403) | ||||||||||||||||||||||||||||||||||
PWSC depreciation (3) | (38) | (11) | (7) | (8) | (12) | ||||||||||||||||||||||||||||||||||
Pro forma Non-GAAP adjusted EBITDA for | $ | 8,889 | $ | 2,929 | $ | 993 | $ | 2,188 | $ | 2,779 | |||||||||||||||||||||||||||||
Includes reduction due to PWI final purchase | $ | 1,857 | $ | - | $ | 1,857 | $ | - | $ | - |
(1) | Investment income arising as part of Extended Warranty segment's minimum holding requirements |
(2) | Realized Gains (losses) resulting from investments held in trust as part of Extended Warranty segment's minimum holding requirements |
(3) | Amounts relating to the sale of PWSC (end of |
(4) | The three months ended |
(5) | Given the non-recurring nature of the PPP forgiveness benefit, the Company has concluded this should be excluded from non-GAAP adjusted EBITDA and pro forma non-GAAP EBITDA. |
Reconciliation of KSX Segment Operating Income to Non-GAAP Adjusted EBITDA
(in thousands)
(UNAUDITED)
Twelve | For the Three Months Ended | |||||||||||||||||||
GAAP Operating Income for KSX segment | $ | 3,548 | $ | 1,126 | $ | 723 | $ | 893 | $ | 806 | ||||||||||
Non-GAAP Adjustments: | ||||||||||||||||||||
Employee costs (1) | 235 | 70 | 55 | 55 | 55 | |||||||||||||||
Total Non-GAAP Adjustments | 235 | 70 | 55 | 55 | 55 | |||||||||||||||
Non-GAAP adjusted EBITDA for KSX segment | $ | 3,783 | $ | 1,196 | $ | 778 | $ | 948 | $ | 861 |
Three | ||||
GAAP Operating Income for KSX segment | $ | 484 | ||
Non-GAAP Adjustments: | ||||
Employee costs (1) | 71 | |||
Total Non-GAAP Adjustments | 71 | |||
Non-GAAP adjusted EBITDA for KSX segment | $ | 555 |
(1) | Costs associated with employees assisting during a transition period and are not expected to be replaced once transition period has ended (approximately one year from acquisition date). |
View original content:https://www.prnewswire.com/news-releases/kingsway-reports-full-year-2022-financial-results-301766185.html
SOURCE
FAQ
What were Kingsway Financial Services' (KFS) revenue figures for 2022?
How much did Kingsway Financial (KFS) earn in adjusted EBITDA for 2022?
What significant acquisitions did Kingsway Financial (KFS) make in 2022?
What was the outcome of Kingsway's (KFS) debt facility amendment?